[go: up one dir, main page]

WO2006022619A3 - Methods for identifying risk of type ii diabetes and treatments thereof - Google Patents

Methods for identifying risk of type ii diabetes and treatments thereof Download PDF

Info

Publication number
WO2006022619A3
WO2006022619A3 PCT/US2004/023590 US2004023590W WO2006022619A3 WO 2006022619 A3 WO2006022619 A3 WO 2006022619A3 US 2004023590 W US2004023590 W US 2004023590W WO 2006022619 A3 WO2006022619 A3 WO 2006022619A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diabetes
type
treatments
identifying risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/023590
Other languages
French (fr)
Other versions
WO2006022619A2 (en
Inventor
Maria L Langdown
Matthew Roberts Nelson
Rikard Henry Reneland
Stefan M Kammerer
Andreas Braun
Carolyn R Hoyal-Wrightson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sequenom Inc
Original Assignee
Sequenom Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sequenom Inc filed Critical Sequenom Inc
Priority to PCT/US2004/023590 priority Critical patent/WO2006022619A2/en
Publication of WO2006022619A2 publication Critical patent/WO2006022619A2/en
Publication of WO2006022619A3 publication Critical patent/WO2006022619A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Provided herein are methods for identifying a risk of type II diabetes in a subject, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating type II diabetes, and therapeutic and preventative methods applicable to type II diabetes. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome.
PCT/US2004/023590 2004-07-22 2004-07-22 Methods for identifying risk of type ii diabetes and treatments thereof Ceased WO2006022619A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2004/023590 WO2006022619A2 (en) 2004-07-22 2004-07-22 Methods for identifying risk of type ii diabetes and treatments thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/023590 WO2006022619A2 (en) 2004-07-22 2004-07-22 Methods for identifying risk of type ii diabetes and treatments thereof

Publications (2)

Publication Number Publication Date
WO2006022619A2 WO2006022619A2 (en) 2006-03-02
WO2006022619A3 true WO2006022619A3 (en) 2006-05-11

Family

ID=35967941

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023590 Ceased WO2006022619A2 (en) 2004-07-22 2004-07-22 Methods for identifying risk of type ii diabetes and treatments thereof

Country Status (1)

Country Link
WO (1) WO2006022619A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012029993A1 (en) * 2010-09-02 2012-03-08 Riken Method of detecting type ii diabetes
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
EP2749569A1 (en) * 2012-12-28 2014-07-02 Annibale Alessandro Puca Variant of BPIFB4 protein
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
US9892234B2 (en) 2014-10-27 2018-02-13 Aseko, Inc. Subcutaneous outpatient management
WO2017031440A1 (en) 2015-08-20 2017-02-23 Aseko, Inc. Diabetes management therapy advisor
AU2018317807A1 (en) * 2017-08-16 2020-02-06 Roxiant ApS VTFT isoform of a BPIFB4 protein for use in neuronal diseases and injuries

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THIGPEN A.E. ET AL: "Tissue distribution and Ontogeny of steroid 5 alpha-reductase isozyme expression", J. CLINICAL INVEST., vol. 92, August 1993 (1993-08-01), pages 903 - 910, XP000647822 *

Also Published As

Publication number Publication date
WO2006022619A2 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
WO2004047514A3 (en) Methods for identifying risk of breast cancer and treatments thereof
GB0514910D0 (en) Method for sequencing a polynucleotide template
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
MX2007006529A (en) Selecting patients for therapy with a her inhibitor.
WO2008061213A3 (en) Genetic variations associated with tumors
DE602005009702D1 (en) ESR1 AND NUTRITIONAL CANCER
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2005062770A3 (en) Method for conducting pharmacogenomics-based studies
ATE437962T1 (en) METHOD FOR THE TREATMENT OF PROLIFERATIVE DISEASES OF BREAST CELLS
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005032495A8 (en) Gene expression profiles and methods of use
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
WO2005034737A3 (en) Methods for diagnosing and treating endoplasmic reticulum (er) stress diseases
WO2008070325A3 (en) Genetic variations associated with tumors
WO2007058968A3 (en) Gene expression profiles and methods of use
WO2006026074A3 (en) Atherosclerotic phenotype determinative genes and methods for using the same
WO2007019312A3 (en) Methods for characterizing and treating cognitive impairment in aging and disease
WO2003101177A3 (en) Diagnosing predisposition to fat deposition and therapeutic methods for reducing fat deposition and treatment of associated conditions
WO2004048546A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2005100611A3 (en) Detection of viral nucleic acid and method for reverse transcribing rna
WO2007006862A3 (en) Method and kit for detecting a risk of coronary heart disease
WO2000058510A3 (en) Schizophrenia associated genes, proteins and biallelic markers

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase